Keytruda — Competitive Intelligence Brief

Keytruda (pembrolizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody; PD-1 inhibitor. Area: Oncology.

marketed Monoclonal antibody; PD-1 inhibitor PD-1 receptor Oncology Monoclonal antibody

Target snapshot

Keytruda (pembrolizumab) — Merck & Co.. Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Keytruda TARGET	pembrolizumab	Merck & Co.	marketed	Monoclonal antibody; PD-1 inhibitor	PD-1 receptor	2014-01-01
Short-term Sintilimab	Short-term Sintilimab	Shanghai Jiao Tong University School of Medicine	marketed	PD-1 inhibitor	PD-1
PD-1 Monoclonal Antibody	PD-1 Monoclonal Antibody	Peking University People's Hospital	marketed	PD-1 inhibitor	PD-1
Tislelizumab and nintedanib	Tislelizumab and nintedanib	The Affiliated Hospital of Qingdao University	marketed	PD-1 inhibitor + tyrosine kinase inhibitor combination	PD-1 (tislelizumab); VEGFR, FGFR, PDGFR (nintedanib)
Chemotherapy+Pembrolizumab.	Chemotherapy+Pembrolizumab.	Tang-Du Hospital	marketed	Chemotherapy + PD-1 inhibitor combination	PD-1 (programmed death receptor 1); chemotherapy targets DNA
K8	K8	Michelle Abou-Jaoude	marketed	PD-1 inhibitor	PD-1
PD-1 combined with chemotherapy	PD-1 combined with chemotherapy	Shandong Provincial Hospital	marketed	PD-1 inhibitor + chemotherapy combination	PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody; PD-1 inhibitor class)

1. Merck & Co. · 1 drug in this class